Lewy bodies (LBs) are cytoplasmic inclusions that represent one of the hallmark neuropathological features of Parkinson's disease (PD) and dementia with Lewy bodies (DLB). First described by Friedrich Lewy in 1912, these spherical proteinaceous aggregates accumulate primarily within neurons and are predominantly composed of the protein alpha-synuclein (α-syn) [1]. The formation and accumulation of Lewy bodies is central to the pathogenesis of these neurodegenerative disorders, and understanding their molecular mechanisms has become a major focus of neuroscience research. [1]
Lewy bodies are not merely passive byproducts of neuronal dysfunction but actively contribute to neurotoxicity through multiple mechanisms, including disruption of cellular homeostasis, impairment of protein quality control systems, and propagation of pathology throughout the brain. The prion-like spreading hypothesis suggests that Lewy body pathology can spread from cell to cell, propagating the disease process across anatomically connected brain regions [2]. [2]
Alpha-synuclein is the principal component of Lewy bodies, comprising approximately 10-15% of the total protein content [3]. This 140-amino acid protein is encoded by the SNCA gene and is normally localized to presynaptic terminals where it regulates synaptic vesicle trafficking and neurotransmitter release [4]. Under pathological conditions, α-syn undergoes a conformational transformation from its native soluble state to form β-sheet-rich fibrils that aggregate into Lewy bodies. [3]
The aggregation of α-syn is facilitated by several factors including post-translational modifications (phosphorylation, ubiquitination, nitration), genetic mutations (A53T, A30P, E46K), and multiplications of the SNCA gene [5]. Phosphorylation at serine-129 (S129) is particularly notable as it is found in over 90% of Lewy body pathology in PD brains and serves as a sensitive marker for Lewy body formation [6]. [4]
Ubiquitin is the second major component of Lewy bodies and serves as a marker of cellular protein degradation pathway involvement [7]. The presence of ubiquitin within Lewy bodies indicates that these inclusions are recognized as abnormal proteins by the cellular quality control machinery, but the degradation systems fail to eliminate them. Ubiquitination of α-syn within Lewy bodies may represent a failed attempt at proteasomal clearance. [5]
Lewy bodies contain numerous other proteins beyond α-syn and ubiquitin: [6]
Lewy body formation follows a nucleation-dependent (seeded) aggregation mechanism. The process begins with the formation of small oligomeric intermediates (dimers, trimers) that serve as nuclei for further growth [14]. These oligomers then elongate by incorporating additional α-syn monomers into the growing fibril structure. The rate-limiting step is the formation of the initial nucleus, which is thermodynamically unfavorable under normal conditions. [7]
Several factors can accelerate nucleation: [8]
| Factor | Mechanism | [9]
|--------|-----------| [10]
| Point mutations (A53T, A30P) | Increase aggregation propensity | [11]
| Gene duplication | Elevated α-syn concentration | [12]
| Oxidative stress | Protein modification, filamentation | [13]
| Metal ions (Fe³⁺, Cu²⁺) | Catalyze aggregation | [14]
| membranes | Surface-catalyzed nucleation | [15]
The accumulation of Lewy bodies reflects a failure of cellular protein quality control systems: [16]
Multiple PTMs promote Lewy body formation: [17]
Brainstem-type Lewy bodies are the classic spherical inclusions with a dense core and surrounding halo, measuring 5-25 μm in diameter [19]. They are predominantly found in the substantia nigra pars compacta, locus coeruleus, and dorsal motor nucleus of the vagus. These inclusions typically display intense immunoreactivity for α-syn and ubiquitin. [18]
Cortical Lewy bodies lack the characteristic halo structure and appear as less defined, diffuse cytoplasmic inclusions [20]. They are more prevalent in the cerebral cortex, limbic system, and basal forebrain. Cortical Lewy bodies are associated with the diffuse Lewy body disease phenotype and often accompany Alzheimer-type pathology. [19]
Limbic-type Lewy bodies represent an intermediate form with features of both brainstem and cortical types. They are primarily located in the amygdala, entorhinal cortex, and cingulate gyrus [21]. [20]
The distribution of Lewy body pathology follows a characteristic pattern that has been formalized in the Braak staging scheme for PD [22]: [21]
This ascending pattern of pathology is consistent with the prion-like propagation hypothesis and explains the progression of motor and non-motor symptoms in PD. [22]
More recent staging systems incorporate both brainstem and cortical Lewy bodies and their relationship to clinical phenotypes [23]: [23]
Lewy bodies are closely associated with neuronal death in Parkinson's disease. The density of Lewy bodies in the substantia nigra correlates with the degree of dopaminergic neuronal loss, though the relationship is not strictly causal [24]. The presence of Lewy bodies may represent a protective cellular response to sequester toxic protein aggregates, as neurons with Lewy bodies can survive for years. [24]
Lewy body-containing neurons exhibit multiple functional impairments: [25]
The distribution of Lewy body pathology correlates with clinical features: [26]
| Clinical Feature | Associated Pathology | [27]
|-----------------|----------------------| [28]
| Resting tremor | Nigrostriatal degeneration | [29]
| Bradykinesia | Motor cortex involvement | [30]
| Cognitive decline | Cortical Lewy bodies | [31]
| Visual hallucinations | Limbic system, visual cortex | [32]
| Autonomic dysfunction | Peripheral nervous system |
Multiple lines of evidence support the hypothesis that Lewy body pathology can propagate between neurons in a prion-like manner [26]:
The spreading of α-syn pathology involves several mechanisms:
Like prions, α-syn aggregates can exist as distinct "strains" with different structural conformations and biological activities [28]. These strains may explain the clinical heterogeneity of Lewy body disorders and their variable response to treatment.
Dementia with Lewy bodies (DLB) is characterized by:
DLB is defined neuropathologically by the presence of diffuse Lewy bodies, particularly in the cerebral cortex and limbic system [29]. Alzheimer-type pathology (amyloid plaques, neurofibrillary tangles) is frequently present and may modify the clinical phenotype.
The overlap between DLB and Alzheimer's disease (AD) is substantial:
Understanding Lewy body formation has led to several therapeutic strategies:
Improving cellular protein quality control:
Blocking prion-like propagation:
Multiple animal models have been developed to study Lewy body formation:
Current models have significant limitations:
Lewy body burden is quantified using stereological methods:
The classic Lewy body exhibits a spherical morphology with a dense eosinophilic core surrounded by a pale halo. Under electron microscopy, the core displays randomly arranged filamentous structures measuring 7-10 nm in diameter, while the halo contains radially oriented filaments [32]. Immunogold labeling confirms α-syn as the primary filament component.
Cortical Lewy bodies differ significantly from brainstem types:
Lewy body disorders primarily affect older adults, with incidence increasing dramatically after age 65. The prevalence of Parkinson's disease with dementia approaches 30% in individuals over 80 years old [33]. Autopsy studies indicate that incidental Lewy bodies may be present in 5-10% of clinically asymptomatic individuals over age 60, suggesting that additional factors determine clinical expression.
Several genetic factors influence Lewy body formation:
Epidemiological studies have identified several environmental risk factors for Lewy body disorders:
Soluble oligomeric intermediates of α-syn are increasingly recognized as the primary neurotoxic species, rather than mature fibrils within Lewy bodies [37]. These oligomers:
Lewy body pathology profoundly affects synaptic function even before overt neuronal loss:
Lewy body formation interferes with axonal transport machinery:
Neuroinflammation accompanies Lewy body pathology:
The relationship between neuroinflammation and LB formation remains complex:
Currently available biomarkers for Lewy body disorders include:
Research biomarkers under development:
Current treatments for Lewy body disorders:
Multiple disease-modifying approaches are in development:
Improving early and accurate diagnosis:
Lewy body formation represents a central pathological process in Parkinson's disease and dementia with Lewy bodies. These cytoplasmic inclusions are composed predominantly of misfolded alpha-synuclein along with numerous associated proteins, and their accumulation reflects a failure of cellular protein quality control systems. The prion-like propagation of Lewy body pathology explains the characteristic spread of neurodegeneration throughout the brain in affected individuals.
Understanding the molecular mechanisms underlying Lewy body formation has provided critical insights into disease pathogenesis and identified multiple therapeutic targets. While current treatments are purely symptomatic, the development of disease-modifying therapies targeting α-syn aggregation, clearance, and propagation offers hope for meaningful intervention in these devastating neurodegenerative disorders.
Conway KA, et al. " Acceleration of oligomerization by the A53T mutation in α-synuclein. Nat Rev Neurosci 2001;2:585-590". 2001. ↩︎
Galvin JE, et al. " Neurofilament proteins in Lewy body disease. Am J Pathol 1999;154:1281-1292". 1999. ↩︎
Auluck PK, et al. " Hsp70 functions in α-synuclein toxicity. Nat Rev Neurosci 2005;6:393-403". 2005. ↩︎
Wood SJ, et al. α-Synuclein aggregation in Parkinson's disease. J Mol Biol 1999;286:333-352. 1999. ↩︎
McNaught KS, et al. " Impaired 26S proteasome function in PD. Exp Neurol 2002;177:301-307". 2002. ↩︎
Mizuno N, et al. " Chaperone-mediated autophagy in neurodegeneration. Nat Rev Neurosci 2006;7:337-344". 2006. ↩︎
Sato K, et al. " Phosphorylation of α-synuclein at Ser129. Nat Rev Neurosci 2013;14:724-735". 2013. ↩︎
Giasson BI, et al. " Nitration of α-synuclein in Lewy bodies. Science 2000;290:985-989". 2000. ↩︎
Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996;55:259-272. 1996. ↩︎
Dickson DW, et al. " Neuropathology of diffuse Lewy body disease. J Neuropathol Exp Neurol 2008;67:14-29". 2008. ↩︎
Braak H, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211. 2003. ↩︎
Braak H, et al. " Pathological markers in diffuse Lewy body disease. J Neurol Sci 1995;129:210-219". 1995. ↩︎
Kosaka K, et al. " Diffuse Lewy body disease. Acta Neuropathol 2014;127:349-364". 2014. ↩︎
Kalia LV, et al. " Clinical correlations with Lewy body pathology. Lancet Neurol 2015;14:1043-1052". 2015. ↩︎
Schapira AH. Mitochondrial dysfunction in Parkinson's disease. Neurochem Int 2012;60:533-541. 2012. ↩︎
Goedert M, et al. " α-Synuclein and neurodegenerative disease. Nat Rev Neurosci 2017;18:251-267". 2017. ↩︎
Brahic M, et al. " Cell-to-cell transmission of α-synuclein aggregates. Nat Rev Neurosci 2016;17:497-506". 2016. ↩︎
Cushman M, et al. " Conformational strains of pathogenic α-synuclein. Nat Rev Neurosci 2010;11:507-516". 2010. ↩︎
McKeith IG, et al. " Consensus guidelines for DLB diagnosis. Neurology 2017;89:88-100". 2017. ↩︎
Wrasidlo W, et al. " A screen for compounds that prevent aggregation of α-syn. Nat Rev Neurosci 2006;7:461-470". 2006. ↩︎
Masliah E, et al. " Effects of α-syn immunization in transgenic mice. Nat Med 2011;17:500-503". 2011. ↩︎
Dickson DW, et al. " Ultrastructural characteristics of Lewy bodies. Acta Neuropathol 1994;88:1-6". 1994. ↩︎
Aarsland D, et al. Prevalence and clinical correlates of dementia in Parkinson's disease. Arch Neurol 2000;57:369-372. 2000. ↩︎
Singleton AB, et al. α-Synuclein locus triplication causes Parkinson's disease. Science 2003;302:841. 2003. ↩︎
Goker-Alpan O, et al. " GBA mutations are associated with earlier onset of PD with LB pathology. Mov Disord 2010;25:1423-1431". 2010. ↩︎
Palu M, et al. " APOE ε4 influences clinical presentation of DLB. Neurology 2001;57:439-445". 2001. ↩︎
Caughey B, et al. " α-Synuclein oligomers and neurotoxicity. Nat Rev Neurosci 2015;16:77-84". 2015. ↩︎
Stoessl AJ, et al. Neuroimaging in Parkinson's disease. Neurobiol Dis 2014;62:86-97. 2014. ↩︎
Mollenhauer B, et al. " CSF biomarkers for α-synuclein pathology. Ann Neurol 2019;85:935-948". 2019. ↩︎
McKeith I, et al. " Efficacy of rivastigmine in DLB. Lancet 2000;356:2031-2036". 2000. ↩︎
Brundin P, et al. " Immunotherapy for neurodegenerative diseases. Nat Rev Neurosci 2016;17:323-324". 2016. ↩︎
Fairfoul G, et al. " α-Synuclein RT-QuIC in CSF of DLB and PD. Ann Neurol 2016;79:1013". 2016. ↩︎